SkinDermic® owns a pipeline of new drugs for the treatment of dermatological diseases (Acne and Acne-prone skin, Kaposi’s sarcoma, Lightening/Melasma).
SkinDermic is a spin-off of Paris Cité and Sorbonne Universities, APHP, INSERM, CNRS. Three patents were filed and correspond to the assets discovered in the context of its research programs.
These patents have all entered into the national phase and are active in several countries including US, EU, CA, JP, CN & AU.
